Zymeworks Gross Margin 2016-2021 | ZYME

Current and historical gross margin for Zymeworks (ZYME) over the last 10 years. The current gross profit margin for Zymeworks as of September 30, 2021 is %.
Zymeworks Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2021-09-30 $0.02B $-0.16B -695.65%
2021-06-30 $0.02B $-0.17B -759.09%
2021-03-31 $0.03B $-0.15B -453.13%
2020-12-31 $0.04B $-0.13B -333.33%
2020-09-30 $0.03B $-0.15B -608.00%
2020-06-30 $0.03B $-0.12B -403.33%
2020-03-31 $0.03B $-0.11B -423.08%
2019-12-31 $0.03B $-0.09B -290.00%
2019-09-30 $0.06B $-0.03B -49.12%
2019-06-30 $0.05B $-0.02B -37.25%
2019-03-31 $0.07B $0.00B 6.15%
2018-12-31 $0.05B $-0.00B -5.66%
2018-09-30 $0.07B $0.02B 25.68%
2018-06-30 $0.07B $0.02B 27.78%
2018-03-31 $0.05B $0.01B 11.76%
2017-12-31 $0.05B $0.01B 19.61%
2017-09-30 $0.00B $-0.03B -1133.33%
2017-06-30 $0.01B $-0.03B -620.00%
2017-03-31 $0.01B $-0.03B -280.00%
2016-12-31 $0.01B $-0.03B -270.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.386B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88